AGI Therapeutics, TPG Capital deal

AGI Therapeutics regained full rights to AGI-010 after TPG Capital's Axcan Pharma Inc. unit and AGI Therapeutics mutually ended a 2006 deal to co-develop the compound in the U.S. and Canada to trea...